Is a
Clinical Study attributes
NCT Number
Trial Recruitment Size
2450
Trial Sponsor
Clinical Trial Start Date
March 3, 2017
0Primary Completion Date
January 26, 2018
0Study Completion Date
January 26, 2018
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Intervention Type
Drug0
Intervention Name
ITCA 650 20/60 mcg/day0
Empagliflozin (oral)0
Glimepiride (oral)0
Interventional Trial Phase
Phase 30
Participating Facility
Official Name
A Phase 3b, Randomized, Active Comparator, Open-label, Multicenter Study to Compare the Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and to Glimepiride as Add-on Therapy to Metformin in Patients With Type 2 Diabetes0
Last Updated
March 7, 2019
0Allocation Type
Randomized0
Intervention Model
Parallel Assignment0
Masking Type
None (Open Label)0
Study summary
A Phase 3b, open-label, randomized, multicenter, efficacy, safety, and tolerability study of ITCA 650 compared to Empagliflozin and to Glimepiride, as add-on therapy to Metformin in patients with Type 2 diabetes.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
